News-Medical.Net on MSN

GeneSight test-guided treatment leads to faster remission and response in patients with depression

Myriad Genetics, Inc., a leader in molecular diagnostic testing and precision medicine, today announced a post-hoc analysis ...

New Post-Hoc Analysis Shows Patients Whose Clinicians Had Access to GeneSight Results for Depression Treatment Are More Likely to Feel Better Sooner

Published in the Oct. 30, 2025 edition of Frontiers in Pharmacology, the new post-hoc analysis showed that patients who took the GeneSight test were at any given time during the 24-week study period ...
TipRanks on MSN

ONO Pharmaceutical’s ONO-1110 Trial: A Potential Game-Changer for Major Depressive Disorder

ONO Pharmaceutical Co (($OPHLF)) announced an update on their ongoing clinical study. Study Overview: ONO Pharmaceutical Co. Ltd is conducting a ...
Mirage News

GeneSight Access Boosts Depression Treatment Outcomes

PRIME Care met both of its prespecified primary outcomes: patients in the PGx-guided arm were less likely to be prescribed an antidepressant medication with a significant gene-drug interaction and ...
Nasdaq

AbbVie to Acquire Gilgamesh Pharmaceuticals' Bretisilocin, a Novel, Investigational Therapy for Major Depressive Disorder, Expanding Psychiatry Pipeline

Gilgamesh's lead asset, bretisilocin (GM-2505), is a potential best-in-class psychedelic compound currently in Phase 2 development for the treatment of major depressive disorder (MDD). Bretisilocin is ...
The Scientist

PTSD Leaves Gene Expression “Scars” on Brain Cells

Single-cell analyses revealed molecular profiles that can distinguish PTSD from depression, potentially leading to better drugs for this psychiatric disorder. To test this hypothesis, Girgenti and his ...